Ernexa Therapeutics Inc. Purchase Obligation, to be Paid, Remainder of Fiscal Year
Ernexa Therapeutics Inc. (ERNA) had Purchase Obligation, to be Paid, Remainder of Fiscal Year of $52.00 thousand as of 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Notes › Commitment and Contingencies
us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2015-05-08
- 2015-03-31: Purchase Obligation, to be Paid, Remainder of Fiscal Year $52.00K.
- 2014-12-31: Purchase Obligation, to be Paid, Remainder of Fiscal Year $423.00K.
- 2014-09-30: Purchase Obligation, to be Paid, Remainder of Fiscal Year $68.00K.
- 2014-06-30: Purchase Obligation, to be Paid, Remainder of Fiscal Year $135.00K.
| Period end | Purchase Obligation, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2015-03-31 | $52.00K 10-Q · filed 2015-05-08 |
| 2014-12-31 | $423.00K 10-Q · filed 2015-05-08 |
| 2014-09-30 | $68.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $135.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $141.00K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $32.00K 10-Q · filed 2014-11-07 |
| 2013-06-30 | $28.00K 10-Q · filed 2013-08-14 |
| 2012-12-31 | $15.00K 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |